Streamlined and focused

24/11/21 -"This looks to be the new motto of Merck’s refurbished R&D pipeline. The strong cut in clinical programmes (50% up to 11/11/2021) has been quietly done. This reminds us of 2014/15, when Merck did ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

24/11/21

Download

You may also be interested by these reports :

01/07/25

Sanofi

Back in late-2023, when Sanofi abandoned its 2025 profitability targets to step up its internal R&D efforts, the management had highlighted 12 ...

26/06/25

PolyPeptide

Downside for 1H25E consensus – FY25E consensus should be fine – Mid-term potential reiterated

24/06/25

Idea Kicker

Just like Big Pharmas in aggregate, Sanofi’s (Buy; France) shares have gone nowhere over the last two years. After collapsing by c.19% in a day in ...

12/06/25

Valuation Wise

Only a month ago we were lamenting the weakness of Pharmas, the second larget sector by market cap.  The tide may have turned, strangely as part ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue